Technical Analysis for ZSAN - Zosano Pharma Corporation

Grade Last Price % Change Price Change
F 0.7589 -1.81% -0.01
ZSAN closed down 3.16 percent on Tuesday, May 11, 2021, on 71 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 12
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical ZSAN trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction -1.81%
Wide Bands Range Expansion -1.81%
Oversold Stochastic Weakness -1.81%
Stochastic Reached Oversold Weakness -4.91%
Wide Bands Range Expansion -4.91%
Oversold Stochastic Weakness -4.91%
New Downtrend Bearish -9.17%
Wide Bands Range Expansion -9.17%
Narrow Range Bar Range Contraction -6.42%
NR7 Range Contraction -6.42%
Older End-of-Day Signals for ZSAN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% 26 minutes ago
Down 2 % 26 minutes ago
Fell Below Previous Day's Low 26 minutes ago
Down 1% about 1 hour ago
1.5x Volume Pace 1 day ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Zosano Pharma Corporation Description

Zosano Pharma Corporation, a clinical stage specialty pharmaceutical company, develops drug formulations for the treatment of various indications. The company delivers formulations through the skin using its proprietary transdermal microneedle patch system. Its lead product candidates comprise Weekly ZP-PTH, a proprietary formulation of parathyroid hormone that has completed a Phase I clinical study for the treatment of severe osteoporosis in women; ZP-Glucagon, a proprietary formulation of glucagon, which has completed a Phase I study for the emergency treatment of severe hypoglycemia; and ZP-Triptan, a proprietary formulation of zolmitriptan that has completed preclinical animal studies for the treatment of migraine. Zosano Pharma Corporation has a strategic partnership and license agreement with Novo Nordisk A/S to develop a microneedle patch product to administer semaglutide for the treatment of type 2 diabetes. The company was founded in 2006 and is headquartered in Fremont, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Diabetes Thyroid Migraine Stage Specialty Pharmaceutical Osteoporosis Transdermal Treatment Of Migraine Hypoglycemia Parathyroid Hormone Emergency Treatment Novo Nordisk Severe Hypoglycemia Triptans Zolmitriptan

Is ZSAN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.05
52 Week Low 0.3275
Average Volume 2,609,003
200-Day Moving Average 1.04
50-Day Moving Average 1.10
20-Day Moving Average 0.91
10-Day Moving Average 0.87
Average True Range 0.07
ADX 27.1
+DI 13.04
-DI 31.07
Chandelier Exit (Long, 3 ATRs ) 0.96
Chandelier Exit (Short, 3 ATRs ) 0.98
Upper Bollinger Band 1.07
Lower Bollinger Band 0.74
Percent B (%b) 0.1
BandWidth 37.00
MACD Line -0.09
MACD Signal Line -0.08
MACD Histogram -0.0049
Fundamentals Value
Market Cap 78.89 Million
Num Shares 102 Million
EPS -2.81
Price-to-Earnings (P/E) Ratio -0.28
Price-to-Sales 0.00
Price-to-Book 1.14
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.83
Resistance 3 (R3) 0.83 0.81 0.82
Resistance 2 (R2) 0.81 0.79 0.81 0.81
Resistance 1 (R1) 0.79 0.79 0.80 0.79 0.81
Pivot Point 0.77 0.77 0.78 0.77 0.77
Support 1 (S1) 0.76 0.76 0.76 0.76 0.73
Support 2 (S2) 0.74 0.75 0.74 0.73
Support 3 (S3) 0.72 0.74 0.73
Support 4 (S4) 0.72